

B2
Claim 5. The method of claim 1, wherein said growth-factor receptor is epidermal
growth-factor receptor (EGFR) [EGFR]

RECEIVED

DEC 15 2008

Sub D5
Claim 17. The method of any one of the previous claims for the prevention or
treatment of disorders associated with or accompanied by a disturbed [, e.g.
pathologically enhanced] growth factor receptor activation.

Sub D5
Claim 19, line 2, please delete "pharmaceutically acceptable composition" and
substitute --pharmaceutical composition-- therefore.

Please add new claim 21 as follows:

Sub D5
Claim 21. The method of claim 17 for the prevention or treatment of disorders
associated with or accompanied by a [disturbed, e.g.] pathologically enhanced growth
factor receptor activation.

REMARKS

Claims 1-20 are currently pending. Claims 1-20 are rejected. Claims 2 and 3 are
objected to. Claim 2 is canceled and claims 1, 5, 17 and 19 amended. New claim 21 is
added. Support for new claim 21 can be found throughout the application as filed
including original claim 17. No new matter has been added. Applicants respectfully
request reconsideration and withdrawal of all rejections.